

## Looking beyond cells

Fibrosis, the excessive accumulation of extracellular matrix proteins in tissues, is a hallmark of many solid tumors, including breast, lung, pancreatic, and liver cancer. Conventional treatments focus on solely targeting cancer cells, overlooking the fibrotic matrix. Presence of excessive matrix proteins are linked to an immune-suppressive environment, treatment resistance and poor patient outcomes.

Precision targeting the matrix offers druggable biological landscape to impact nodes that drive disease progression.

## Platform to precision target the fibrotic matrix

The ubiquity of matrix proteins makes precision targeting highly complex. Novel targeted approaches to modulate fibrotic matrix are essential to offset toxicity and enhance efficacy. Our peptide platform is built on the foundational understanding of matrix remodelling and mechano-biological changes in fibrotic diseases. The peptides bind with high affinity to conformational signatures associated predominately with fibrotic matrix.

Tandem peptides can be conjugated to various functional modalities to map, target and treat fibrotic matrix. When compared to antibodies, matrix binding peptides are non-immunogenic, cost effective, scalable and can be engineered to tune binding and pharmacokinetic properties while maintaining high tissue access.

## Market opportunity

The current immuno-oncology market (USD 80 B, CAGR 15.4%) only addresses blood cancers and is inaccessible for solid tumors due to the unique challenges posed by fibrosis.

Our solution of targeted extracellular matrix modulatory drug is a promising class of therapeutics that have the potential to revolutionize immuno-oncology treatments for fibrotic cancers.

We are well positioned based on robust proof of mechanism validated in multiple in vitro and in vivo disease models, a strong IP position and successful proof of concept data in fibrotic tumor model.


## Investment

TandemTx seeks a seed round investment of USD 5 M in 2023 to finance key milestones

- Proof-of-concept studies in multiple fibrotic tumor indications with 1-2 pre-clinical lead candidates
- Platform optimisation to develop next generation of matrix targeting peptide
- PK and conjugation optimisation to have value driving partnering assets

## Support

Innosuisse - Swiss Innovation Agency



## Company

Incorporated in June 2023 as a Spin-off from Swiss Federal Institute of Technology, Zürich, Switzerland.(ETHZ)

## Technology

Platform is based on Matrix Targeting Peptides that selectively target extracellular matrix alterations in fibrotic diseases.

## Investment opportunity USD 5 M

## Financing to date

USD 1.20m total  
USD 970k non dilutive grants  
USD 170k convertible loan

## Founding Team

### Dr. Mamta Chabria

CEO

Co-inventor, Ex-Roche, Pharma & Diagnostic

### Prof. Viola Vogel, ETHZ

Scientific Advisor

Matrix biology & In vitro disease modeling

### Dr. Martin Behe, PSI

Scientific Advisor

Radiopharm & Peptide Chemistry

## Contact

Tandem Therapeutics AG  
Wagistrasse 18,  
8952 Schlieren  
Switzerland

Email: [info@tandem-tx.com](mailto:info@tandem-tx.com)

Phone: +41786841169